Navigation Links
BioMed Realty Trust Reports Third Quarter 2008 Financial Results
Date:10/29/2008

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc. (NYSE: BMR), a real estate investment trust focused on providing real estate to the life science industry, today announced financial results for the third quarter ended September 30, 2008.

Highlights:

-- Quarterly total revenues increased 24.6% to $80.8 million from

$64.8 million in the third quarter 2007

-- Completed delivery of the 84,000 square foot build-to-suit laboratory

and office facility at our Towne Centre Drive campus in San Diego to

our tenant, Illumina, Inc.

-- Continued delivery of space to Beth Israel Deaconess Medical Center,

Inc. at the Center for Life Science | Boston, bringing total occupancy

at the building to nearly 80% at the end of the quarter

-- Executed leasing transactions during the quarter representing nearly

200,000 square feet:

o Six new leases totaling approximately 52,000 square feet, including

an approximately 28,000 square foot lease with Nteryx, Inc. at our

Ardenwood Boulevard property in the Fremont/Newark submarket of the

San Francisco Bay Area

o Seven leases amended to extend their terms totaling approximately

147,000 square feet, including a 15-year extension on approximately

91,000 square feet leased to Regeneron Pharmaceuticals, Inc.,

expanding Regeneron's long-term commitment at our Landmark at

Eastview property in New York to over 348,000 square feet

-- Funds from operations (FFO) for the quarter increased 15.5% from the

third quarter 2007 to $35.6 million, or $0.48 per diluted share

"Our continued successes on the operating front, combined with our conservative approach to our capital structure, have enabled us to maintain our focus throughout these extremely turbulent, challenging times, and position us well to take advantage of the opportunities we see in our business. We remain confident in the fundamental long-term demand drivers for the life science industry, and in turn for life science real estate," commented Alan D. Gold, President and Chief Executive Officer of BioMed Realty Trust.

Third Quarter 2008 Financial Results

Rental revenues for the quarter were $59.4 million, representing a 20.2% increase versus the third quarter of 2007. Same property net operating income increased 7.3% on a cash basis for the third quarter of 2008 compared to the third quarter of 2007.

Total revenues for the quarter were $80.8 million, compared to $64.8 million in the third quarter of 2007. Net income available to common stockholders for the quarter was $13.0 million, or $0.18 per diluted share, compared to $12.2 million, or $0.19 per diluted share, in the third quarter of 2007.

FFO during the quarter was $35.6 million, representing a 15.5% increase versus the third quarter of 2007. FFO per diluted share was $0.48 for the third quarter of 2008 versus $0.45 in the third quarter of 2007.

FFO is a supplemental non-GAAP financial measure used in the real estate industry to measure and compare the operating performance of real estate companies. A complete reconciliation containing adjustments from GAAP net income available to common stockholders to FFO and a definition of FFO are included at the end of this release.

Financing Activity

As of September 30, 2008, the company's consolidated debt included fixed-rate mortgage indebtedness with an aggregate outstanding principal amount of $354.8 million, including $9.3 million of debt premium, and a weighted-average effective interest rate of 5.5% at quarter-end; the company's $250 million secured term loan, with a weighted-average effective interest rate of 4.1% at quarter-end; $175 million aggregate principal amount of 4.50% exchangeable senior notes due 2026; $266.7 million in outstanding borrowings under the company's $600 million unsecured revolving line of credit, with a weighted-average effective interest rate of 3.8% at quarter-end; and $501.0 million in outstanding borrowings under the company's acquisition and construction loan secured by the Center for Life Science | Boston property, with a weighted-average effective interest rate of 4.4% at quarter-end. The company's debt to total capitalization ratio was 41.0% at September 30, 2008.

After the quarter ended, on October 6, 2008, the company completed the sale of 8,625,000 shares of common stock, raising net proceeds of approximately $212.4 million after deducting underwriter discounts and commissions and estimated expenses. The net proceeds were utilized to repay a portion of the outstanding borrowings on our $600 million unsecured line of credit and for other general corporate and working capital purposes.

"We have maintained our consistently conservative approach to managing our balance sheet and we were pleased to be able to further fortify our balance sheet through our October 2008 common stock offering. We appreciate the consistent support we have received from our shareholders and lenders," commented Kent Griffin, Chief Financial Officer of BioMed Realty Trust.

Portfolio Update

As of September 30, 2008, BioMed Realty Trust owned or had interests in 112 buildings, located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey. The company's portfolio was comprised of the following, with its operating portfolio 89.0% leased to 115 tenants, as of September 30, 2008:

Rentable

Square Feet

Operating portfolio 7,304,971

Repositioning and redevelopment properties 1,676,651

Construction in progress 1,437,000

Total portfolio 10,418,622

Land parcels 1,367,000

Total proforma portfolio 11,785,622

Following the end of the quarter, on October 3, 2008, a portion of the parking spaces at the garage located on the company's Center for Life Science | Boston property were sold for approximately $29.0 million pursuant to an agreement assumed by the company in connection with its acquisition of the property in November 2006.

On October 14, 2008, the company acquired the minority interest in the entity that owns the 530 Fairview Avenue property in Seattle for approximately $2.6 million; as a result, the company owns 100% of the property.

Quarterly Distributions

BioMed Realty Trust's board of directors previously declared a third quarter 2008 dividend of $0.335 per share of common stock, and a dividend of $0.46094 per share of the company's 7.375% Series A Cumulative Redeemable Preferred Stock for the period from July 16, 2008 through October 15, 2008.

Earnings Guidance

Having reported results for the first nine months of 2008, the company has narrowed its 2008 earnings guidance. The company has also adjusted its earnings guidance to reflect the impact of the October 2008 common stock offering. The company's revised 2008 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below.

2008

(Low - High)

Projected net income per diluted share available

to common stockholders $0.71 - 0.74

Add:

Minority interest in operating partnership $0.03

Real estate depreciation and amortization $1.10

Projected FFO per diluted share $1.84 - $1.87

The company's initial 2009 guidance for net income per diluted share and FFO per diluted share is set forth and reconciled below.

2009

(Low - High)

Projected net income per diluted share available

to common stockholders $0.54 - 0.74

Add:

Minority interest $0.02

Real estate depreciation and amortization $1.04

Projected FFO per diluted share $1.60 - $1.80

Consistent with the 2008 guidance, the company's 2009 guidance does not include the impact of future acquisition activities. In addition, the company's 2009 guidance includes the estimated impact of the change in accounting for its exchangeable senior notes, the company's October 2008 common stock offering and higher anticipated financing costs.

The foregoing estimates are forward-looking and reflect management's view of current and future market conditions, including certain assumptions with respect to leasing activity, rental rates, occupancy levels, financing transactions, interest rates, and the amount and timing of development and redevelopment activities. The company's actual results may differ materially from these estimates.

Supplemental Information

Supplemental operating and financial data are available in the Investor Relations section of the company's web site at http://www.biomedrealty.com.

Teleconference and Web Cast

BioMed Realty Trust will conduct a conference call and audio web cast at 10:00 a.m. Pacific Time (1:00 p.m. Eastern Time) on Thursday, October 30, 2008 to discuss the company's financial results and operations for the quarter. The call will be open to all interested investors either through a live audio web cast at the Investor Relations section of the company's web site at http://www.biomedrealty.com and http://www.earnings.com, or live by calling (866) 314-5050 (domestic) or (617) 213-8051 (international) with call ID number 52610625. The call will be archived for 30 days on both web sites. A telephone playback of the conference call will also be available from 2:00 p.m. Pacific Time on Thursday, October 30, 2008 through midnight Pacific Time on Tuesday, November 4, 2008 by calling (888) 286-8010 (domestic) or (617) 801-6888 (international) and using access code 61247789.

About BioMed Realty Trust

BioMed Realty Trust, Inc. is a real estate investment trust (REIT) focused on Providing Real Estate to the Life Science Industry(R). The company's tenants primarily include biotechnology and pharmaceutical companies, scientific research institutions, government agencies and other entities involved in the life science industry. BioMed Realty Trust owns or has interests in 69 properties, representing 112 buildings with approximately 10.4 million rentable square feet, including approximately 1.4 million square feet of development in progress. The company also owns undeveloped land parcels adjacent to existing properties that it estimates can support up to 1.4 million rentable square feet. The company's properties are located predominantly in the major U.S. life science markets of Boston, San Diego, San Francisco, Seattle, Maryland, Pennsylvania and New York/New Jersey, which have well-established reputations as centers for scientific research. Additional information is available at http://www.biomedrealty.com.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

(Financial Tables Follow)

BIOMED REALTY TRUST, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands)

September 30, 2008 December 31, 2007

(Unaudited)

ASSETS

Investments in real estate, net $2,915,675 $2,805,983

Investments in unconsolidated

partnerships 20,296 22,588

Cash and cash equivalents 23,451 13,479

Restricted cash 8,291 8,867

Accounts receivable, net 7,284 4,457

Accrued straight-line rents, net 52,721 36,415

Acquired above-market leases, net 4,661 5,745

Deferred leasing costs, net 107,145 116,491

Deferred loan costs, net 12,057 15,567

Other assets 70,837 27,676

Total assets $3,222,418 $3,057,268

LIABILITIES AND STOCKHOLDERS' EQUITY

Mortgage notes payable, net $354,828 $379,680

Secured construction loan 500,998 425,160

Secured term loan 250,000 250,000

Exchangeable senior notes 175,000 175,000

Unsecured line of credit 266,660 270,947

Security deposits 7,469 7,090

Dividends and distributions payable 29,441 25,596

Accounts payable, accrued expenses,

and other liabilities 106,553 95,871

Acquired below-market leases, net 19,212 23,708

Total liabilities 1,710,161 1,653,052

Minority interests 14,968 17,280

Stockholders' equity:

Preferred stock 222,413 222,413

Common stock 717 656

Additional paid-in capital 1,432,350 1,277,770

Accumulated other comprehensive loss (35,657) (21,762)

Dividends in excess of earnings (122,534) (92,141)

Total stockholders' equity 1,497,289 1,386,936

Total liabilities and

stockholders' equity $3,222,418 $3,057,268

BIOMED REALTY TRUST, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except share and per share data)

For the Three Months For the Nine Months

Ended September 30, Ended September 30,

2008 2007 2008 2007

(Unaudited) (Unaudited)

Revenues:

Rental $59,381 $49,382 $163,946 $146,351

Tenant recoveries 20,911 15,084 53,297 47,264

Other income 519 366 1,697 8,445

Total revenues 80,811 64,832 218,940 202,060

Expenses:

Rental operations 17,027 12,789 44,345 38,784

Real estate taxes 6,763 5,079 16,948 16,538

Depreciation and

amortization 21,506 17,665 58,525 54,556

General and

administrative 4,589 5,283 16,428 15,990

Total expenses 49,885 40,816 136,246 125,868

Income from

operations 30,926 24,016 82,694 76,192

Equity in net loss

of unconsolidated

partnerships (208) (261) (338) (694)

Interest income 110 239 370 809

Interest expense (13,035) (7,043) (28,600) (21,013)

Income from

continuing

operations

before minority

interests 17,793 16,951 54,126 55,294

Minority interests

in continuing

operations of

consolidated

partnerships (11) 51 (4) (61)

Minority interests in

continuing

operations of

operating

partnership (559) (545) (1,767) (1,821)

Income from

continuing

operations 17,223 16,457 52,355 53,412

Income from

discontinued

operations before

(loss)/gain on sale

of assets and

minority interests - - - 639

(Loss)/gain on sale

of real estate assets - (1) - 1,087

Minority interests

attributable to

discontinued

operations - - - (74)

(Loss)/income

from

discontinued

operations - (1) - 1,652

Net income 17,223 16,456 52,355 55,064

Preferred stock

dividends (4,241) (4,241) (12,722) (12,628)

Net income

available to

common

stockholders $12,982 $12,215 $39,633 $42,436

Income from

continuing operations

per share available

to common

stockholders:

Basic and diluted

earnings per share $0.18 $0.19 $0.57 $0.62

Net income per share

available to common

stockholders:

Basic and diluted

earnings per share $0.18 $0.19 $0.57 $0.65

Weighted-average

common shares

outstanding:

Basic 71,513,333 65,308,702 68,995,015 65,300,802

Diluted 74,714,841 68,274,908 72,120,329 68,262,086

BIOMED REALTY TRUST, INC.

FUNDS FROM OPERATIONS

(In thousands, except share and per share data)

The following table provides the calculation of our FFO and a reconciliation to net income available to common stockholders (in thousands, except per share amounts):

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

(Unaudited) (Unaudited)

Net income available

to common stockholders $12,982 $12,215 $39,633 $42,436

Adjustments:

Minority interests in

operating partnership 559 545 1,767 1,895

Loss/(gain) on sale of

real estate assets - 1 - (1,087)

Depreciation and

amortization -

unconsolidated

partnerships 524 366 1,425 745

Depreciation and

amortization -

consolidated entities -

discontinued operations - - - 228

Depreciation and

amortization -

consolidated entities -

continuing operations 21,506 17,665 58,525 54,556

Depreciation and

amortization - allocable

to minority interest

of consolidated

joint ventures (8) - (25) -

Funds from operations

available to common

shares and partnership

and LTIP units $35,563 $30,792 $101,325 $98,773

Funds from operations

per share - diluted $0.48 $0.45 $1.40 $1.45

Weighted-average common

shares outstanding

- diluted 74,714,841 68,274,908 72,120,329 68,262,086

We present funds from operations, or FFO, available to common shares and partnership and LTIP units because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs, many of which present FFO when reporting their results. FFO is intended to exclude GAAP historical cost depreciation and amortization of real estate and related assets, which assumes that the value of real estate assets diminishes ratably over time. Historically, however, real estate values have risen or fallen with market conditions. Because FFO excludes depreciation and amortization unique to real estate, gains and losses from property dispositions and extraordinary items, it provides a performance measure that, when compared year over year, reflects the impact to operations from trends in occupancy rates, rental rates, operating costs, development activities and interest costs, providing perspective not immediately apparent from net income. We compute FFO in accordance with standards established by the Board of Governors of the National Association of Real Estate Investment Trusts, or NAREIT, in its March 1995 White Paper (as amended in November 1999 and April 2002). As defined by NAREIT, FFO represents net income (computed in accordance with GAAP), excluding gains (or losses) from sales of property, plus real estate related depreciation and amortization (excluding amortization of loan origination costs) and after adjustments for unconsolidated partnerships and joint ventures. Our computation may differ from the methodology for calculating FFO utilized by other equity REITs and, accordingly, may not be comparable to such other REITs. Further, FFO does not represent amounts available for management's discretionary use because of needed capital replacement or expansion, debt service obligations, or other commitments and uncertainties. FFO should not be considered as an alternative to net income (loss) (computed in accordance with GAAP) as an indicator of our financial performance or to cash flow from operating activities (computed in accordance with GAAP) as an indicator of our liquidity, nor is it indicative of funds available to fund our cash needs, including our ability to pay dividends or make distributions.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. Serica Technologies Expands Facilities in Massachusetts, Combines State-Of-The-Art Textile Engineering and Biomedical Manufacturing
2. BioMed Realty Trust Declares Third Quarter 2007 Common Stock and Preferred Stock Dividends
3. CryoLife Signs Distribution Agreement for Inclusion of BioGlue(R) Surgical Adhesive in Hernia Repair Kit with Proxy Biomedical Surgical Meshes
4. Verax Biomedical Receives 510 (k) Clearance from FDA for Platelet PGD Test
5. SLIM Search, Inc. Sponsors Next Generation Sequencing Conference for the Biomedical Market
6. NCIIA Announces Launch of 4th Annual Student Biomedical Innovation Competition
7. New Scientists Boost Disease-based Research at Boston Biomedical Research Institute
8. Foundation for Biomedical Research Board Chairman Awarded Congressional Gold Medal
9. Crux Biomedical Announces First Successful U.S. Implant of Its New Retrievable Inferior Vena Cava (IVC) Filter
10. Environmental Tectonics Corporations BioMedical Division Announces New Contract
11. Avery Biomedical Devices, Inc. Appoints Elefteriades to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... TORONTO , June 23, 2016 /PRNewswire/ - ... Ontario biotechnology company, Propellon ... the development and commercialization of a portfolio of ... cancers. Epigenetic targets such as WDR5 represent an ... contribute significantly in precision medicine for cancer patients. ...
(Date:6/23/2016)... ... June 23, 2016 , ... ... (Yeast and Mold) microbial test has received AOAC Research Institute approval 061601. , ... tests introduced last year,” stated Bob Salter, Vice President of Regulatory and Industrial ...
Breaking Biology Technology:
(Date:6/2/2016)... 2016   The Weather Company , an IBM Business ... industry-first capability in which consumers will be able to interact ... questions via voice or text and receive relevant information about ... Marketers have long sought an advertising solution that can ... personal, relevant and valuable; and can scale across millions of ...
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... DALLAS , May 12, 2016 ... has just published the overview results from the Q1 ... of the recent wave was consumers, receptivity to a ... wearables data with a health insurance company. ... choose to share," says Michael LaColla , CEO ...
Breaking Biology News(10 mins):